Ultracet is indicated for the short-term management of acute pain. 7/19/2007 8:27:44 AM Midland Company (MLAN) reported that its second quarter net income ...
In addition, Par and its subsidiary Kali Laboratories acknowledged that the reissue patent for Ultracet (tramadol/acetaminophen) is valid and enforceable, ...
As part of the settlement, Par/Kali acknowledged that the reissue patent for ULTRACET® is valid and enforceable, and that they infringed it by selling ...
Par Pharmaceutical Cos. and Ortho-McNeil Pharmaceutical Inc. have settled a patent infringement case regarding Ortho-McNeil's Ultracet pain medication. ...
Inc. says it has settled patent litigation relating to painkiller Ultracet, a short-term treatment for acute pain, and entered into a licensing agreement ...
Ultracet (37.5 mg tramadol HCl/325 mg acetaminophen tablets) is indicated for the short-term (five days or less) management of acute pain. ...
Par Pharmaceutical Cos. and Ortho-McNeil Pharmaceutical Inc. have settled a patent infringement case regarding Ortho-McNeil's Ultracet pain medication. ...
Par received approval from the US Food and Drug Administration and began marketing its generic version of Ultracet(R) in April 2005. ...
Par launched the generic version of Ultracet in April 2005. The deal ends a patent lawsuit filed by Ortho-McNeil against Par subsidiary Kali Laboratories, ...
The settlement includes Par entering into a consent judgment that the patent for Ultracet is valid and enforceable.